In our recent study, we found that the rate of ZFHX3 mutation was 19% in Chinese patients, which is higher than that in a previous study, and that ZFHX3 mutation could serve as a biomarker for immunotherapy response in SCLC patients [61]. The gene discussed is ZFHX3; the disease is small cell lung carcinoma.